Approval · Notice of Compliance 18020 · 2016
ZITHROMAX: Notice of Compliance 18020
Issued April 22, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18020
- Date
- April 22, 2016
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of 500 mg tablets
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZITHROMAX | Not yet assigned | — |
| ZITHROMAX FOR INTRAVENOUS INJECTION | Not yet assigned | — |
Medicinal ingredients
- AZITHROMYCIN 100 MG per 5ML
- AZITHROMYCIN 200 MG per 5ML
- AZITHROMYCIN 250 MG per TAB
- AZITHROMYCIN 600 MG per TAB
- AZITHROMYCIN 500 MG per VIAL